Alpha Tau Delta

Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society for Radiation Oncology

Retrieved on: 
Friday, October 21, 2022
Memorial Sloan Kettering Cancer Center, U.S. Securities and Exchange Commission, Alpha Sigma Tau, XV, SEC, Health care, Squamous cell carcinoma, Neoplasm, MD Anderson Cancer Center, Xi, NASDAQ, Patient, Society, Seed, Medication, Research, Annual report, IRB, Annual general meeting, Risk, Nasdaq, Cancer, Technology, Vulva, Health Canada, CHUM, Private Securities Litigation Reform Act, Mouse, Epithelium, Company, Radiation therapy, ASTRO, Alpha Tau Delta, Polish Radiation Research Society, Breast, Safety, Vii, 100,000, United Kingdom, Clinical trial, GLOBE, Cambridge University Hospitals NHS Foundation Trust, University, COVID-19, Booth, Radiation Research, Pancreas, Poster, Jewish General Hospital, Pharmaceutical industry, Alpha, Tel Aviv University

JERUSALEM, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”)  (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today its participation in the upcoming 2022 Annual Meeting of the American Society for Radiation Oncology (“ASTRO”), being held October 23 – 25, 2022 in San Antonio, TX, where the Company will be at Booth #3719. Participants interested in meeting with the Alpha Tau team at the conference can do so by booking a slot via the following link: https://calendly.com/michaelt-alpha-dart/. Ahead of the conference, the Company is pleased to announce a number of recent developments:

Key Points: 
  • Participants interested in meeting with the Alpha Tau team at the conference can do so by booking a slot via the following link: https://calendly.com/michaelt-alpha-dart/ .
  • The trial seeks to measure the feasibility, safety, efficacy and immunological response associated with treatment with the Alpha DaRT.
  • Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain.
  • These forward-looking statements should not be relied upon as representing Alpha Tau's views as of any date subsequent to the date of this press release.

Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and Frontiers in Oncology) of Two Landmark Pre-Clinical Studies Demonstrating Significant Potential Synergies Between the Al

Retrieved on: 
Thursday, September 8, 2022
Neoplasm, Squamous cell carcinoma, COVID-19, Glioblastoma, Technology, GBM, Frontiers, XV, Research, Alpha Sigma Tau, Immunity, Immunophenotyping, MDSC, Brain, Trial of the century, Time, Xi, Gene expression, Canadian International Council, ASTRO, Risk, Mouse, Society, Biology, Blood, VEGF, DNA repair, DNA, SEC, U.S. Securities and Exchange Commission, SCC, Pembrolizumab, 100,000, PD-1, TMZ, GLOBE, CD31, Nasdaq, FDA, Immune system, American Society for Radiation Oncology, Cell death, Cell proliferation, RNA transfection, Annual report, Private Securities Litigation Reform Act, CTO, Vii, Alpha Tau Delta, Patient, Medical imaging, Pharmaceutical industry, Vaccine, Oncology, Bevacizumab, Physics, Radiation therapy, Tel Aviv University, Alpha

JERUSALEM, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau") (Nasdaq: DRTS and DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the acceptance of two landmark pre-clinical studies in major peer-reviewed journals, both demonstrating the significant potential synergies between Alpha DaRT therapy and standard-of-care solid tumor therapies used today.

Key Points: 
  • We are very excited to have these fantastic results recognized by two leading journals in our field, said Alpha Tau CEO Uzi Sofer.
  • We also are impressed by the synergies we see with other mechanisms such as anti-angiogenesis and continue to explore those in parallel as well.
  • These results demonstrate potential synergies with immune stimulation in mice and support the further exploration of the Alpha DaRT as a compelling local radiation therapy with the potential to induce antitumor immunity.
  • In this pre-clinical study, Squamous Cell Carcinoma (SCC) tumor-bearing mice were treated with Alpha DaRT in combination with an anti-PD1 therapy (aPD-1).

Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer

Retrieved on: 
Thursday, September 1, 2022
Pharmacia, Neoplasm, COVID-19, CEO, Technology, Cancer prevention, Cancer, XV, Research, Squamous cell carcinoma, Alpha Sigma Tau, Therapy, Pfizer, Private Securities Litigation Reform Act, Xi, Risk, OSI, Hope, SEC, U.S. Securities and Exchange Commission, McGill University, 100,000, GLOBE, Nasdaq, Erlotinib, Chief commercial officer, Annual report, Marketing, OSI Pharmaceuticals, Vii, Alpha Tau Delta, Bristol Myers Squibb, Patient, Pharmaceutical industry, Tel Aviv University, Alpha

JERUSALEM, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that Peter Melnyk, a member of its board of directors, has resigned from the Companys Board of Directors in order to assume the full-time position of Alpha Taus Chief Commercial Officer.

Key Points: 
  • JERUSALEM, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that Peter Melnyk, a member of its board of directors, has resigned from the Companys Board of Directors in order to assume the full-time position of Alpha Taus Chief Commercial Officer.
  • Before that, he served as Chief Commercial Officer of Novocure, and led the construction of the global commercial platform and infrastructure for the launch of Novocures Optune product.
  • Prior to OSI, Mr. Melnyk was executive director of oncology at Pfizer and Pharmacia and a director of oncology at Bristol-Myers Squibb.
  • We are thrilled to bring Peter in to lead our commercialization efforts, said Alpha Tau CEO Uzi Sofer.

Alpha Tau Medical Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 25, 2022
COVID-19, Technology, Research, Squamous cell carcinoma, Liver, Xi, Risk, Carcinosarcoma, U.S. Securities and Exchange Commission, SCC, 100,000, GLOBE, Company, Investor, PMDA, Prostate cancer, Vii, Alpha Tau Delta, Patient, Neoadjuvant therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Head, Food, SEC, Nasdaq, FDA, Environmental protection, Annual report, Trial of the century, KOL, D, Financial result, GBM, Skin cancer, IDE, Health Canada, D&O, Pancreatic tumor, BCC, Prostate, Private Securities Litigation Reform Act, Marketing, RECIST, Neoplasm, Ministry, XV, Alpha Sigma Tau, Pancreatic cancer, Neck, G&A, Medical device, Medical imaging, Pharmaceutical industry, Renewable energy, Alpha, Tel Aviv University

JERUSALEM, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported second quarter 2022 financial results and provided a corporate update.

Key Points: 
  • The Company expects to treat its first patient in this study later in 2022-
    JERUSALEM, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the Company), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, reported second quarter 2022 financial results and provided a corporate update.
  • First patient treated in a feasibility study evaluating the Alpha DaRT as a neoadjuvant therapy in patients with prostate cancer.
  • Expecting first patient treated in U.S. multi-center pivotal trial in recurrent cutaneous SCC in the second half of 2022.
  • Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors.

Alpha Tau and MIM Software Announce Collaboration for Alpha DaRT Treatment Planning

Retrieved on: 
Monday, August 22, 2022
Neoplasm, COVID-19, CEO, Technology, 3D, Cancer, XV, Research, OH, Alpha Sigma Tau, Brain, Xi, Solution, Software, Risk, Cardiac imaging, Data management, Radiation therapy, SEC, Nuclear medicine, U.S. Securities and Exchange Commission, Method, 100,000, Urology, GLOBE, Health, Pancreas, Nasdaq, Radiation, Annual report, MIM, Private Securities Litigation Reform Act, Vii, Alpha Tau Delta, Patient, Pharmaceutical industry, Medical imaging, Radiology, Tel Aviv University, Brachytherapy, Neuroimaging, Alpha

JERUSALEM and CLEVELAND, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Today, Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, and MIM Software Inc. (MIM Software), a leading global provider of medical imaging software, announced a collaboration between the two companies to provide treatment planning software for clinical sites using the Alpha DaRT therapy.

Key Points: 
  • JERUSALEM and CLEVELAND, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Today, Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, and MIM Software Inc. (MIM Software), a leading global provider of medical imaging software, announced a collaboration between the two companies to provide treatment planning software for clinical sites using the Alpha DaRT therapy.
  • Under the terms of the agreement, the parties will collaborate on the use of MIMs software suite, including MIM Symphony and MIMcloud, for development of new features and support for the Alpha DaRT across multiple potential indications, integration into all clinical trials involving the Alpha DaRT, and bundling the MIM software with the Alpha DaRT for future commercial sales in territories where the Alpha DaRT and MIMs software are both approved.
  • The MIM Symphony treatment planning software guides clinicians through an easy step-by-step process to place Alpha DaRT sources precisely and create a patient-personalized treatment plan.
  • Our collaboration with Alpha Tau is an excellent opportunity for MIM to impact radiotherapy and patient outcomes, said Andy Nelson, CEO of MIM Software.

Alpha Tau Hosting Key Opinion Leader Meeting on Alpha DaRT Clinical Trials

Retrieved on: 
Tuesday, July 5, 2022
MSKCC, Patient, Sun Yat-sen University Cancer Center, Head, Research, Breast cancer, Harvard Medical School, Q&A, GU, Gastrointestinal cancer, GLOBE, Squamous cell carcinoma, COVID-19, Breakfast, SCC, Yale University, Radiation therapy, XV, Radiation, Annual report, Xi, Memorial Sloan Kettering Cancer Center, Alpha Tau Delta, Brachytherapy, Lung cancer, Prostate cancer, Learning Technology Partners, U.S. Securities and Exchange Commission, 100,000, KOL, Neoplasm, Private Securities Litigation Reform Act, Technology, Nasdaq, SEC, Risk, Greenberg, Thomas Jefferson University, Time, Webcast, Vii, Cancer, Oncology nursing, Pharmaceutical industry, Medical imaging, Chemistry, Alpha, Tel Aviv University, Oncology, MD

The meeting will feature presentations from KOLs Michael J. Zelefsky, MD, Memorial Sloan Kettering Cancer Center, Mark DAndrea, MD, University Cancer Centers, and Robert Den, MD, Alpha Tau's Chief Medical Officer, who will discuss Alpha Taus therapy (the Alpha DaRT radiation technology) and the Companys clinical trial outlook.

Key Points: 
  • The meeting will feature presentations from KOLs Michael J. Zelefsky, MD, Memorial Sloan Kettering Cancer Center, Mark DAndrea, MD, University Cancer Centers, and Robert Den, MD, Alpha Tau's Chief Medical Officer, who will discuss Alpha Taus therapy (the Alpha DaRT radiation technology) and the Companys clinical trial outlook.
  • During the KOL presentations, Alpha Taus recent clinical trials, upcoming U.S. pivotal trial in recurrent cutaneous Squamous Cell Carcinoma (SCC), other upcoming clinical trials, and the Companys pre-clinical work on potential immunological effects of the Alpha DaRT technology will be discussed.
  • Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors.
  • Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain.

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT™ in Recurrent Cutaneous SCC

Retrieved on: 
Wednesday, June 8, 2022
The Company, 100,000, Tel Aviv University, Seed, Company, IDE, Research, Xi, Neoplasm, Food, Annual report, Nasdaq, Efficacy, Risk, FDA, Investigator's brochure, Vii, SCC, Sofer, Patient, Private Securities Litigation Reform Act, Technology, Trial of the century, COVID-19, Safety, XV, SEC, Alpha Tau Delta, Clinical trial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Squamous cell carcinoma, U.S. Securities and Exchange Commission, Pharmaceutical industry, Alpha

"We are very excited about the upcoming commencement of our U.S. pivotal study, undoubtedly our most significant clinical trial to date," commented Alpha Tau CEOUzi Sofer.

Key Points: 
  • "We are very excited about the upcoming commencement of our U.S. pivotal study, undoubtedly our most significant clinical trial to date," commented Alpha Tau CEOUzi Sofer.
  • Yaniv Sagie, Alpha Tau VP Quality and Regulatory Affairs, noted, "This amazing milestone represents the culmination of Alpha Tau's rigorous teamwork and unwavering commitment to quality and regulatory excellence."
  • Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral insertion of radium-224 impregnated seeds.
  • Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain.

Alpha Tau Announces Resignation of Gary Leibler from its Board of Directors

Retrieved on: 
Tuesday, June 7, 2022
100,000, Ramot at Tel Aviv University, Seed, Company, Research, Xi, Neoplasm, Annual report, Nasdaq, Risk, Vii, Sofer, Patient, Private Securities Litigation Reform Act, Technology, COVID-19, NASDAQ, XV, SEC, Alpha Tau Delta, Alpha Sigma Tau, Cancer, U.S. Securities and Exchange Commission, Pharmaceutical industry, Alpha

JERUSALEM, June 7, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) (Nasdaq: DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that Mr. Gary Leibler has resigned from the Company's board of directors and its audit committee, for reasons unrelated to the Company.

Key Points: 
  • JERUSALEM, June 7, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) (Nasdaq: DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that Mr. Gary Leibler has resigned from the Company's board of directors and its audit committee, for reasons unrelated to the Company.
  • "I wish to thank Gary for his years of dedicated service to the Company, as a member of the board of directors since the early days of Alpha Tau," commented Alpha Tau CEOUzi Sofer.
  • Gary Leibler, who also serves as the founder and managing partner of Shavit Capital, added, "After serving as a board member of Alpha Tau for a number of years, I have decided to resign for personal reasons.
  • I am more confident than ever that Alpha Tau is on the path to becoming a leading company in the treatment of cancer patients throughout the world.

Alpha Tau Announces Results of First US Clinical Trial of Alpha DaRT™ in Malignant Skin & Soft Tissue Cancers, Showing Complete Response in All Ten Treated Tumors at Approximately 12 Weeks and No Product-Related Serious Adverse Events

Retrieved on: 
Monday, January 10, 2022
Clinical trial, Memorial Sloan Kettering Cancer Center, SEC, Safety, Form, Risk, Skin, Acquisition, Alpha Sigma Tau, Shareholder, Neoplasm, Failure, Business architecture, Security (finance), 100,000, Name, Memorial, Patient, Commissioner, Sale, U.S. Securities and Exchange Commission, HCCC, Securities Act of 1933, Register, Mergers and acquisitions, Registration statement, Alpha Tau Delta, Research, RECIST, Skin cancer, Tripura Merger Agreement, Private Securities Litigation Reform Act, Sumathi Best Television Current Reporting Award, Nasdaq, Technology, XV, Prospectus, News, COVID-19, FDA, Xi, Business, Radiation, Vii, Medical imaging, Pharmaceutical industry, Alpha, Tel Aviv University

Alpha Tau CEO Uzi Sofer remarked, "Alpha Tau is incredibly focused on the US market, which we see as the paramount market for the Alpha DaRT.

Key Points: 
  • Alpha Tau CEO Uzi Sofer remarked, "Alpha Tau is incredibly focused on the US market, which we see as the paramount market for the Alpha DaRT.
  • "We are extremely encouraged by the initial efficacy results from our US pilot trial," said Alpha Tau CMO, Dr. Robert Den.
  • We look forward to continued examination of the potential of the Alpha DaRT, backed by the expediency of the FDA's breakthrough device designation."
  • Achieving a 100 percent complete response rate for a new cancer therapy with no product-related serious adverse events is remarkable."

Alpha Tau Announces Completion of Enrollment in First US Clinical Trial of Alpha DaRT™ and Achievement of First Primary Objective

Retrieved on: 
Monday, October 25, 2021
100,000, Squamous cell carcinoma, Registration statement, Research, Quality of life, Tripura Merger Agreement, Technology, Skin cancer, Securities Act of 1933, Failure, Name, Vii, Alpha Sigma Tau, Neoplasm, Security (finance), U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, FDA, HCCC, SEC, Xi, Sumathi Best Television Current Reporting Award, Risk, Form, XV, COVID-19, Skin, Alpha Tau Delta, Nasdaq, Prospectus, Acquisition, Business, Business architecture, Register, Sale, Shareholder, Mergers and acquisitions, Pharmaceutical industry, Medical imaging

As such, the trial has met its first primary objective, in demonstrating feasibility of successful delivery of the Alpha DaRT.

Key Points: 
  • As such, the trial has met its first primary objective, in demonstrating feasibility of successful delivery of the Alpha DaRT.
  • Tumor response, a secondary objective of the trial, will be assessed in each patient three months after Alpha DaRT removal.
  • The pilot study is designed to evaluate the feasibility of Alpha DaRT in treating ten subjects with malignant skin and superficial soft tissue tumors.
  • "The novelty of the Alpha DaRT has sparked great excitement in the U.S. oncology community as evidenced by our brisk accrual," said Alpha Tau CMO, Dr. Robert Den.